Genetically modified chickens as bioreactors for protein-based drugs

Area of Science:

• Biotechnology
• Molecular Biology
• Animal Science

Background:

• Traditional protein drug production methods face challenges in cost and efficiency.
• Transgenic animal bioreactors are an emerging alternative for recombinant protein production.
• Various species have been explored, but avian systems show unique promise.

Purpose of the Study:

• To review and compare different protein drug expression systems.
• To highlight the potential of genetically modified chickens as a bioreactor system.
• To discuss the advantages of avian bioreactors for therapeutic protein production.

Main Methods:

• Comparative analysis of microbial, yeast, plant, and mammalian cell expression systems.
• Focus on genetically modified chickens utilizing ovarian cell expression.
• Application of advanced gene editing technologies like CRISPR/Cas9.

Main Results:

• Avian bioreactors offer short production cycles and high efficiency.
• Expression products in egg whites are easier to purify and closer to their natural state.
• CRISPR/Cas9 enables precise genetic modification for improved protein characteristics.

Conclusions:

• Genetically modified chickens represent a highly promising and sustainable bioreactor system for protein-based drugs.
• This technology can lead to enhanced production of recombinant therapeutics with reduced immunogenicity.
• Avian bioreactors have significant potential for production, research, and sustainable development.